

119TH CONGRESS
2D SESSION

H. R. 9699

To require the Department of Health and Human Services to release documents, communications, and other information relating to most favored nation pricing agreements and other private or confidential drug pricing deals struck with manufacturers, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

JULY 15, 2026

Ms. CHU (for herself, Ms. CASTOR of Florida, Ms. LEE of Pennsylvania, Mr. PAPPAS, Mr. BEYER, Ms. CLARKE of New York, Ms. DELBENE, Mr. CARSON, Ms. DEXTER, Mr. DOGGETT, Mr. EVANS of Pennsylvania, Ms. GOODLANDER, Ms. MATSUI, Ms. MCCOLLUM, Ms. MOORE of Wisconsin, Mr. MFUME, Ms. NORTON, Mr. PANETTA, Ms. ROSS, Ms. SCHAKOWSKY, Mr. SCHNEIDER, Mr. TAKANO, Ms. TLAIB, and Ms. WILLIAMS of Georgia) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Budget, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

To require the Department of Health and Human Services to release documents, communications, and other information relating to most favored nation pricing agreements and other private or confidential drug pricing deals struck with manufacturers, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

1 **SECTION 1. SHORT TITLE.**

2 This Act may be cited as the “Drug Deal Disclosure
3 Act”.

4 **SEC. 2. RELEASE OF INFORMATION RELATING TO MOST-FA-**
5 **VORED-NATION PRICING AGREEMENTS.**

6 (a) PUBLIC RELEASE OF INFORMATION.—

7 (1) IN GENERAL.—Not later than 30 days after
8 the date of enactment of this Act, the Secretary of
9 Health and Human Services (referred to in this Act
10 as the “Secretary”), subject to subsections (b) and
11 (c), shall make publicly available in a centralized,
12 searchable, and downloadable format all records,
13 documents, communications, meeting notes, memo-
14 randa, directives, logs, metadata, contracts, and
15 agreements as provided by the Department of
16 Health and Human Services, or any other Federal
17 department, agency, or office that possesses such in-
18 formation to which the Secretary does not have di-
19 rect access, that relate to any agreement, including
20 any agreement described in paragraph (2) or (3), be-
21 tween an Executive Office of the President, the De-
22 partment of Health and Human Services, the De-
23 partment of Commerce, or another Federal depart-
24 ment, agency, or office and any drug manufacturer
25 entered into on or after January 20, 2025, that in-
26 cludes any of the following provisions:

1 (A) That the manufacturer or any of its
2 subsidiaries shall offer reduced prices on any of
3 its drugs to levels that make reference to the
4 prices paid for drugs in nations other than the
5 United States, including under the Medicare
6 program under title XVIII of the Social Secu-
7 rity Act (42 U.S.C. 1395 et seq.) and the Med-
8 icaid program under title XIX of such Act (42
9 U.S.C. 1396 et seq.).

10 (B) That the manufacturer or any of its
11 subsidiaries shall offer or expand its offerings
12 of direct-to-consumer drug sales or discounts on
13 its drugs through the website of such manufac-
14 turer or subsidiary, partnerships with other en-
15 tities, or any government-sponsored platform,
16 including TrumpRx.

17 (C) That goods imported or produced by
18 the manufacturer or any of its subsidiaries shall
19 be excluded or exempt from any duties or other
20 import restrictions.

21 (D) That the manufacturer or any of its
22 subsidiaries shall further invest money or re-
23 sources into the United States or repatriate rev-
24 enue made in nations other than the United
25 States.

1 (E) That the manufacturer or any of its
2 subsidiaries shall receive special treatment, such
3 as an exemption from, or specialized predeter-
4 mined conditions of participation for, any dem-
5 onstration project proposed or implemented by
6 the Center for Medicare and Medicaid Innova-
7 tion, including the Global Benchmark for Effi-
8 cient Drug Pricing “GLOBE” Model, and the
9 Guarding U.S. Medicare Against Rising Drug
10 Costs “GUARD” Model.

11 (F) That the manufacturer or any of its
12 subsidiaries shall contribute to, or be guaran-
13 teed purchasing agreement for, the Strategic
14 National Stockpile established under section
15 319F–2 of the Public Health Service Act (42
16 U.S.C. 247d–6b).

17 (G) That the manufacturer or any of its
18 subsidiaries shall receive a Commissioner’s Na-
19 tional Priority Review Voucher through the
20 pilot program of the Food and Drug Adminis-
21 tration.

22 (2) AGREEMENTS.—The agreements described
23 in this paragraph, and for which public disclosure is
24 required under paragraph (1), include the agree-
25 ments publicly announced by an Executive Office of

1 the President or the applicable drug manufacturer,
2 as follows:

3 (A) AbbVie Inc. on January 12, 2026.

4 (B) Amgen Inc. on December 19, 2025.

5 (C) AstraZeneca plc. on October 10, 2025.

6 (D) Boehringer Ingelheim Pharma-
7 ceuticals, Inc. on December 19, 2025.

8 (E) Bristol Myers Squibb on December 19,
9 2025.

10 (F) Eli Lilly & Company on November 6,
11 2025.

12 (G) EMD Serono Inc. on October 16,
13 2025.

14 (H) Genentech, Inc. on December 19,
15 2025.

16 (I) Gilead Sciences, Inc. on December 19,
17 2025.

18 (J) GSK plc. on December 19, 2025.

19 (K) Johnson & Johnson, Inc. on January
20 8, 2026.

21 (L) Merck & Co., Inc. on December 19,
22 2025.

23 (M) Novartis AG on December 19, 2025.

24 (N) Novo Nordisk Inc. on November 6,
25 2025.

1 (O) Pfizer Inc. on September 30, 2025.

2 (P) Regeneron Pharmaceuticals, Inc. on
3 April 23, 2026.

4 (Q) Sanofi S.A. on December 19, 2025.

5 (3) SUBSEQUENT AGREEMENTS.—If, after the
6 date of enactment of this Act, an Executive Office
7 of the President or any other Federal department,
8 agency, or office enters into an agreement with a
9 drug manufacturer or any of its subsidiaries that
10 meets the criteria described in paragraph (1), or
11 modifies or amends an agreement listed in para-
12 graph (2), not later than 30 days after the date of
13 ratification of such new agreement, the Secretary
14 shall disclose information about such agreement as
15 described in paragraph (1).

16 (b) PROHIBITED GROUNDS FOR WITHHOLDING.—No
17 record shall be withheld, delayed, or redacted on the basis
18 of reputational harm or political sensitivity, including to
19 any government official, public figure, or manufacturer.

20 (c) PERMITTED WITHHOLDINGS.—The Secretary
21 may withhold or redact the segregable portions of agree-
22 ments required to be disclosed under subsection (a)(1)
23 that include proprietary pricing information, pricing infor-
24 mation that manufacturers are legally prohibited from dis-
25 closing based on the law of a nation other than the United

1 States or as part of a settlement agreement or court direc-
2 tive, or information that is protected from disclosure
3 under other applicable law, provided that the Secretary—

4 (1) discloses whether the Secretary has been
5 provided access to confidential pricing information
6 by each individual manufacturer; and

7 (2) includes with any such redaction or with-
8 holding a written justification, and ensures that such
9 written justification is published in the Federal Reg-
10 ister and submitted to Congress.

11 **SEC. 3. REPORT TO CONGRESS.**

12 Not later than 15 days after the completion of the
13 release of agreements listed under section 2(a)(2), the Sec-
14 retary shall submit to the Committee on Finance and the
15 Committee on Health, Education, Labor, and Pensions of
16 the Senate and the Committee on Energy and Commerce,
17 the Committee on Education and Workforce, and the
18 Committee on Ways and Means of the House of Rep-
19 resentatives a report listing—

20 (1) all documents and information released and
21 withheld; and

22 (2) a summary of redactions and withholdings
23 made, including legal basis for such redactions and
24 withholdings.

1 **SEC. 4. CONGRESSIONAL BUDGET OFFICE AND GOVERN-**
2 **MENT ACCOUNTABILITY OFFICE ANALYSIS.**

3 Not later than 90 days after the completion of the
4 release of agreements listed under section 2(a)(2), the Di-
5 rector of the Congressional Budget Office and the Comp-
6 troller General of the United States, jointly, shall publish
7 a report on the economic and budgetary effects of all
8 agreements disclosed under section 2, including—

9 (1) the expected economic and budgetary con-
10 sequences of each such agreement;

11 (2) an analysis of direct cost savings that indi-
12 viduals in the United States have received and can
13 expect to receive, by insurance status, including un-
14 insured individuals, as a consequence of the agree-
15 ments;

16 (3) a budget analysis of the impacts of the
17 agreements on the Medicare program under title
18 XVIII of the Social Security Act (42 U.S.C. 1395 et
19 seq.), the Medicaid program under title XIX of such
20 Act (42 U.S.C. 1396 et seq.), and qualified health
21 plans offered through the American Health Benefit
22 Exchanges established under section 1311 or 1321
23 of the Patient Protection and Affordable Care Act
24 (42 U.S.C. 18031; 18041); and

25 (4) any impact, or expected impact, on—

1 (A) drug price competition (such as
2 through shifts from the use of generic drugs to
3 brand name drugs);

4 (B) section 1128B of the Social Security
5 Act (commonly referred to as the “Federal
6 Anti-Kickback Statute” (42 U.S.C. 1320a–7b));
7 and

8 (C) health plan formulary design (such as
9 cost shifting, adverse events for health plans,
10 and spending acceleration).

○